ESSA Pharma Inc. (EPIX)
| Market Cap | 257.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.80M |
| Shares Out | 44.24M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,533 |
| Open | 6.12 |
| Previous Close | 6.12 |
| Day's Range | 5.71 - 6.22 |
| 52-Week Range | 2.56 - 11.67 |
| Beta | 1.69 |
| Analysts | Buy |
| Price Target | 17.00 (+193.61%) |
| Earnings Date | May 7, 2024 |
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouve... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for EPIX stock is "Buy" and the 12-month stock price forecast is $17.0.
News
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no...
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA , March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achievi...
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023
Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scien...
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developin...
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 re...
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developin...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Enter...
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma to Present at JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enr...
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada , April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on develo...
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC pati...
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment
Shares of Essa Pharma Inc. EPIX, +1.38% fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson JNJ, +1.49% suspended enrollment in a Phase 1 clinical trial for Essa's exper...
ESSA Provides an Update on its Clinical Collaboration with Janssen
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...